From Focus:
Earliest Cancer Trials May Offer Lower Risk But Lower Benefit
The earliest clinical tests of experimental cancer drugs seem to have become safer and slightly less effective for patients, report Thomas G. Roberts and his colleagues in the Nov. 3 Journal of the American Medical Association. The analysis is the first systematic review of phase I oncology trials in more than a decade. The authors speculate that the improved risk-benefit ratio may be due, in part, to the current targeted and less toxic compounds being used and, in part, to a greater attention to the safety of human subjects.

Lab Works

StudenTalk

HMS Wins Wind Energy in Conservation Contest
Fifty percent or more of the people working in five HMS buildings pledged to conserve energy over the next year, earning the buildings renewable energy certificates and distinguishing the School among higher-ed purchasers of renewable energy.

Student Scene